Company intelligence / Profile preview

Virogin Biotech

Shanghai, China

Ownership: Private
Development stage: Other

Overview

Virogin’s most advanced assets include an HSV-1 based oncolytic virus in Phase 2 clinical trials, with mRNA vaccine candidates for oncology and infectious diseases in Phase 2 or earlier. Preclinical and early clinical data show promising immunogenicity and safety; clinical efficacy is under investigation.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Oncolytic virusmRNA vaccineProphylactic vaccine
Industry: Biotech

Drug pipeline

1 asset

HCC-oAd-WNTi

Unknown

Partnerships

CNBG (a Sinopharm subsidiary)Zhujiang Hospital

Beyond the preview

Go deeper on Virogin Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Virogin Biotech.

Explore the full profile